Stratrix
Competitors · Stryker

Who are Stryker’s competitors?

Stryker names 15 companies as competitors in its latest annual report, on 4 fronts. 10 companies name Stryker back.

Skip to the field, head to head ↓Stryker company profile

Competitors it names1510-K for fiscal 2025
Companies that name it10in their own annual reports
Revenue, 2025$25.1B+11% on a year
Net margin13%Medtronic 13% · Baxter International −9%
Stratrix’s Take

Stryker faces a different set of rivals on each front

Stryker's annual report names 15 competitors, but not as one crowd. It sorts them into four fronts: endoscopy, medical, instruments, and vascular and neuro cranial. In the first it says, "We are one of seven leading global competitors in Endoscopy". In the other three it is one of five. Only three names show up twice: ConMed Linvatec, Medtronic and Johnson & Johnson MedTech. The medical front shares no names with the rest.

Rivals see the same thing from their side. Enovis points to Stryker, Zimmer Biomet and DePuy Synthes in reconstructive. Integra puts Stryker beside Medtronic, Steris and B. Braun in its CSS business. Conmed lists it among joint and sports medicine names such as Smith & Nephew and Arthrex. Each rival meets Stryker in one corner, not across the whole company.

So Stryker's position isn't one contest. It is several, each with its own opponents and its own pace. Stryker brought in $25.1 billion with 11% growth and a 13% net margin. Medtronic, the largest name that appears twice, brought in $36.4 billion with 8% growth and the same margin. Asking who Stryker's competitor is gets a weak answer. Asking which front you mean gets a useful one.

The fronts

Where Stryker says it competes

Leading global endoscopy competitors
Karl Storz GmbH & Co.Olympus OpticalSmith & NephewConMed LinvatecArthrexSTERIS
“We are one of seven leading global competitors in Endoscopy; the other six being”
In its own words · 10-K for fiscal 2025
Leading global medical competitors
Baxter InternationalZoll MedicalMedline IndustriesFerno-Washington
“We are one of five leading global competitors in Medical; the other four being Baxter International Inc., Zoll Medical Corporation, Medline Industries and Ferno-Washington, Inc.”
In its own words · 10-K for fiscal 2025
Leading global instruments competitors
Zimmer BiometMedtronicJohnson & Johnson MedTechConMed Linvatec
“We are one of five leading global competitors in Instruments; the other four being Zimmer Biomet Holdings, Inc. (Zimmer), Medtronic plc (Medtronic), Johnson & Johnson MedTech (a subsidiary of Johnson & Johnson) and ConMed Linvatec, Inc. (a subsidiary of CONMED Corporation).”
In its own words · 10-K for fiscal 2025
Vascular and neuro cranial competitors
MedtronicJohnson & Johnson MedTechTerumoPenumbra
“We are one of five leading global competitors in Vascular and Neuro Cranial; the other four being Medtronic, Johnson & Johnson MedTech, Terumo Corporation and Penumbra, Inc.”
In its own words · 10-K for fiscal 2025
Named back

Who names Stryker as a competitor

Steris2026

“On a product basis, competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron and Wassenburg.”

10-K for 2026

“Our business is in a very competitive and evolving field, that faces competition from large established orthopedic companies such as (but not limited to) Medtronic, Stryker, Globus Medical, and DePuy-Synthes that possess considerably more resources than Bone Biologics.”

10-K for 2025
Conmed2025

“We compete with Smith & Nephew, plc; Arthrex, Inc.; Stryker Corporation; Johnson & Johnson: DePuy Mitek, Inc.; Zimmer Biomet, Inc.; Globus Medical, Inc.; and Treace Medical Concepts, Inc.”

10-K for 2025
Enovis2025

“Key competitors for our Reconstructive segment include Stryker, Zimmer Biomet, and DePuy Synthes, the medical device business within Johnson & Johnson.”

10-K for 2025

“We believe that our significant competitors are Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, and Smith + Nephew.”

10-K for 2025

“Our competitors for CSS include divisions within Medtronic, Inc., Stryker Corporation, Steris PLC, and B. Braun Medical, Inc.”

10-K for 2025

“Our primary competitors in our spine market are Medtronic, Stryker Corporation, and Johnson & Johnson.”

10-K for 2025

“Our most notable competitors are Boston Scientific, Medtronic, Stryker (now including Inari Medical), Terumo and several private companies.”

10-K for 2025

“Sports Medicine global market sharea,b In Sports Medicine, Smith+Nephew holds a leading position behind Arthrex, and also competes against Stryker and DePuy Synthes.”

20-F for 2025

“In the global markets for our knees, hips, and S.E.T. products, our major competitors include Johnson & Johnson MedTech (formerly the DePuy Synthes Companies of Johnson & Johnson), Stryker Corporation and Smith & Nephew plc.”

10-K for 2025
Head to head

The field, from the filings

CompanyFiscal yearRevenueGrowthNet marginEmployees
Stryker2025$25.1B+11%13%56,000
MedtronicFY to Apr 2026$36.4B+8%13%–
Baxter International2025$11.2B+6%−9%–
Zimmer Biomet Holdings2025$8.2B+7%9%–
Smith & Nephew2025$6.2B+6%10%–
SterisFY to Mar 2026$5.9B+9%13%18,000
Globus Medical2025$2.9B+17%18%6,000
Enovis2025$2.2B+7%−53%7,802
Integra Lifesciences Holdings2025$1.6B+2%−32%4,427
Merit Medical Systems2025$1.5B+12%8%7,500
Penumbra2025$1.4B+17%13%4,700

Each company’s latest fiscal year as reported to the SEC, in US dollars; fiscal years end in different months. Rivals that report outside the US or in other currencies are not shown.

Customers

How concentrated Stryker’s customers are

“Revenue related to customer lease agreements sold under these arrangements represented less than 4 % of our total revenue for 2025 , 2024 and 2023 .”
In its own words · 10-K for fiscal 2025
The moves

What the rivals have done lately

MedtronicAcquired CathWorks

“On April 20, 2026, the Company acquired all the remaining outstanding shares of CathWorks Ltd. (CathWorks), a privately held medical device company, for $525 million of consideration transferred, including $115 million of contingent cons…” filing

MedtronicAcquired Scientia Vascular

“On June 12, 2026, the Company closed on the acquisition of all outstanding shares of Scientia Vascular (Scientia) (a privately held company).” filing

Baxter InternationalAcquired Zosyn rights from a subsidiary of Pfizer

“Under the terms of the acquisition, we paid the acquisition price of $122 million and received specified intellectual property, including patent rights, in the first quarter of 2022 and received additional intellectual property, includin…” filing

Smith & NephewAcquired Integrity Orthopaedics

“On 21 January 2026, we completed the acquisition of Integrity Orthopaedics, Inc, a US-based early stage commercial developer of Tendon Seam™, an innovative rotator cuff repair (RCR) system designed to significantly reduce re-tear rates a…” filing

Decisions that shaped the field

Medtronic Bought Its Way Into Everything. The Market Just Asked It to Stop.2025Never undone
Questions

Asked about Stryker’s competitors

Who are Stryker's competitors?

In its annual report for fiscal 2025, Stryker names 15 competitors across 4 fronts: leading global endoscopy competitors, leading global medical competitors, leading global instruments competitors and vascular and neuro cranial competitors. 10-K for fiscal 2025

Which companies name Stryker as a competitor?

10 companies in our coverage name it in their own annual reports: Steris, Bone Biologics, Conmed, Enovis, Globus Medical, Integra Lifesciences Holdings, Merit Medical Systems, Penumbra, Smith & Nephew and Zimmer Biomet Holdings.

How does Stryker compare with its rivals?

Stryker reported $25.1B in revenue in its latest fiscal year, +11% on a year, with a 13% net margin. Medtronic: $36.4B, 13% net margin; Baxter International: $11.2B, −9% net margin.

What are the alternatives to Stryker?

The companies Stryker itself names as competitors are listed above, front by front, each in its own report’s words. Which matters for a given buyer depends on the job, not the list.

Is your best customer building your replacement?

How much of your revenue comes from somebody who is also trying to replace you?

See the pack →

Sources: Stryker’s annual report for fiscal 2025; the annual reports of the companies that name it; each company’s financial data as reported to the SEC; Stratrix Decision Records. Analysis and data, not advice.

For information and strategic analysis only, not investment advice. Stratrix does not recommend buying, selling or holding any security.

Tools to try

More from Stratrix

The Business Model Wizard

Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.

Free · about twelve minutesBuild your Model Thesis →

Stratrix Team

Every Casebook, three Strategy Packs a seat each year and Ask Stratrix, for teams that face these decisions all year.

$1,999 a year · $499 a seatWhat is included →

New analyses, by email

The defining moves in business, and what they teach, as they publish.

We'll email you a link to confirm. Unsubscribe anytime. Privacy policy.